Investigating how reactivating a tumor suppressor gene can affect cancer cells
Project 2: To determine the consequences of activating Rb function in cancer cells
This study is looking at how turning back on a gene called Rb can help slow down cancer growth, and it's for people with cancer who want to know more about how new treatments might work better for them.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project ID | NIH-11046672 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of the Rb tumor suppressor gene in cancer cells, particularly how reactivating this gene can suppress cancer progression. The study employs a combination of genetic, cell biological, biochemical, and structural methods, including the use of a novel mouse model that allows researchers to turn Rb function on and off. By examining the effects of Rb re-activation in cancer cells that have lost its function, the research aims to uncover the mechanisms that enable these cells to respond to existing cancer therapies, specifically Cdk4/6 inhibitors.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with cancers where the Rb gene is inactive but can potentially be reactivated through treatment.
Not a fit: Patients whose cancers do not involve the Rb gene or those who have already exhausted all treatment options may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved cancer treatments by enhancing the effectiveness of existing therapies that target the Rb pathway.
How similar studies have performed: Previous research has shown promising results with Cdk4/6 inhibitors in cancer treatment, indicating that exploring Rb re-activation could be a valuable and novel approach.
Where this research is happening
Stanford, United States
- Stanford University — Stanford, United States (Active)
Researchers
- Principal investigator: Sage, Julien — Stanford University
- Study coordinator: Sage, Julien
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.